E-Pharmacy / Diagnostics Platforms
Side-by-side audit
Company A
WatchPharmEasy
Healthcare / Pharmacy / Diagnostics
Consolidated revenue (+3.7% YoY)
₹5,872 Cr
Net loss reduction (₹2,534 → ₹1,572 Cr)
-38%
Company B
WatchTata 1mg
E-pharmacy / Healthtech / Diagnostics
Consolidated revenue (+19.6% YoY)
₹2,353 Cr
Consolidated PAT (loss narrowed 13%)
-₹271 Cr
The 30-Second Summary
Two Indian consumer-health groups. Same FY2025 audit period. Two different legal and entity pathways for capital deployment.
-
PharmEasy (API Holdings Limited): consolidated revenue ₹5,872 Cr (+3.7%), net loss ₹1,572 Cr (-38%). 31 consolidated subsidiaries. Gross goodwill ₹8,364 Cr; ₹4,850 Cr (58%) cumulatively impaired.
-
Tata 1mg (Tata 1mg Technologies Pvt Ltd): consolidated revenue ₹2,353 Cr (+19.6%), net loss ₹271 Cr (-13%). 100% owned by Tata Digital. Gross goodwill ₹5.93 Cr. No cumulative impairment.
The ₹4,850 Cr cumulative goodwill write-down at PharmEasy is what reading the FY25 audit shows from the acquisition era. Tata 1mg's audit does not carry that line.
What Each Audit Captures
Both entities are holding companies for an operating group. Both have standalone P&Ls that look very different from their consolidated P&Ls. The construction strategies differ.
The structural fact behind each audit
PharmEasy (API Holdings Limited)
Acquisition-built group, 31 consolidated subsidiaries.
API Holdings Limited is a Public Limited holding company incorporated 2019. The 31 consolidated subsidiaries include Thyrocare Technologies (separately listed), Nueclear Healthcare (PET-CT imaging), Docon Technologies, and ~28 regional pharma-distribution entities acquired through the Aknamed B2B network. Gross goodwill from these acquisitions sits at ₹8,364 Cr on the consolidated balance sheet, the recorded cost of the acquisition-led buildout.
Tata 1mg (Tata 1mg Technologies Pvt Ltd)
Post-acquisition expansion largely within a single-parent structure.
The original 1mg entity was acquired by Tata Digital Private Limited in 2021-22; Tata Digital now owns 100% of Tata 1mg Technologies Pvt Ltd. Post-acquisition expansion has happened largely within the single-parent structure rather than through further entity-level acquisitions visible at the operating-group layer. The current consolidated group includes operating subsidiaries that run the pharmacy and diagnostics business, a UAE entity (Urban Living Technologies LLC), and an insurance advisory subsidiary. Goodwill on the consolidated balance sheet is ₹5.93 Cr.
→ One group continued expanding through multi-entity acquisitions. The other's post-acquisition expansion happened largely inside a single-parent structure. The audit lines that record each approach are different.
The core insight
Same category, two different group construction strategies. The audit shapes are not interchangeable.
The Numbers, Side by Side
Consolidated revenue (FY2025)
PharmEasy
₹5,872 Cr
+3.7% YoY, scale leader
Tata 1mg
₹2,353 Cr
+19.6% YoY, growing faster off a smaller base
The gap: PharmEasy is 2.5x the revenue. Tata 1mg is growing 5x as fast.
Consolidated net loss (FY2025)
PharmEasy
-₹1,572 Cr
down 38% from -₹2,534 Cr
Tata 1mg
-₹271 Cr
down 13% from -₹313 Cr
The gap: Both losses narrowed. PharmEasy's reduction is larger in absolute rupees (₹962 Cr) and percentage.
Gross goodwill on the consolidated balance sheet
PharmEasy
₹8,364 Cr
cumulative impairment ₹4,850 Cr (58%); net ₹3,513 Cr
Tata 1mg
₹5.93 Cr
no cumulative impairment recognised
The gap: The single line that captures the difference in construction strategy. PharmEasy carries the cumulative record of paid acquisition premium. Tata 1mg's group is built largely inside a single parent's equity envelope.
Consolidated borrowings
PharmEasy
₹2,034 Cr
halved from ₹4,098 Cr in FY24
Tata 1mg
₹655 Cr
up ₹290 Cr from ₹365 Cr in FY24; entirely current
The gap: Opposite directions. PharmEasy is deleveraging; Tata 1mg is expanding working-capital borrowings to fund the group's cash burn and capex.
Consolidated net worth
PharmEasy
+₹3,272 Cr
up from ₹2,588 Cr
Tata 1mg
-₹351.70 Cr
down from -₹93.66 Cr
The gap: PharmEasy has positive consolidated net worth despite ₹4,850 Cr of cumulative goodwill write-down. Tata 1mg's negative consolidated net worth reflects accumulated group losses against parent equity; the standalone net worth at Tata 1mg is +₹1,339 Cr because the parent's investment in subsidiaries is carried at cost there. The support exists because Tata Digital sits above the structure; without that support, the balance-sheet interpretation would differ materially.
Operating cash flow (FY2025)
PharmEasy
-₹224 Cr
from -₹61 Cr in FY24 (worsened)
Tata 1mg
-₹202 Cr
from -₹271 Cr in FY24 (improved)
The gap: Similar absolute cash burn. Opposite directions. PharmEasy's OCF deteriorated; Tata 1mg's improved ₹69 Cr.
Standalone vs Consolidated, Both Entities
Both audits include a standalone P&L and a consolidated P&L. Reading either as "the company's revenue" without naming which is being read produces different conclusions.
Standalone revenue (FY2025)
PharmEasy (API Holdings standalone)
₹550 Cr
largely intercompany management and IP fees from 31 subsidiaries
Tata 1mg (parent entity standalone)
₹375 Cr
intercompany platform/IP/services fees from operating subsidiaries
The gap: Both standalone revenue figures are intercompany in nature. Neither is end-customer revenue.
Standalone PAT (FY2025)
PharmEasy (API Holdings standalone)
-₹1,435 Cr
includes ₹830 Cr standalone exceptional items (impairment of subsidiary investments)
Tata 1mg (parent entity standalone)
+₹65 Cr
up from +₹22 Cr; profitable at the parent layer both years
The gap: API Holdings' standalone carries the parent-level finance costs and subsidiary-investment impairments. Tata 1mg's standalone collects intercompany fees and does not carry equivalent write-downs.
What the standalone-vs-consolidated split reveals about each construction strategy
PharmEasy
The standalone records the cost of holding 31 subsidiaries.
API Holdings' standalone P&L includes ₹383 Cr of finance costs on the borrowings it has historically carried at the parent level and ₹830 Cr of exceptional items reflecting impairment of subsidiary investments. The standalone loss of ₹1,435 Cr is the parent's own audit of the cost of holding the acquired group, separately from the consolidated operating result.
Tata 1mg
The standalone records the platform fees collected from subsidiaries.
Tata 1mg Technologies' standalone P&L records ₹375 Cr of intercompany platform/IP/services revenue. Finance costs at the parent layer are negligible (₹2.56 Cr). Investment in subsidiaries is carried at cost (₹1,226 Cr); no parent-level impairment has been recognised. The standalone profit of ₹65 Cr is the platform-fee collection net of the parent's own operating costs.
→ Same accounting concept (standalone holding company P&L). Two different content profiles, shaped by how each group's capital deployment happened through different legal and entity pathways.
The Goodwill Mechanism
The ₹8,358 Cr difference in gross goodwill between the two consolidated balance sheets is the single largest forensic distinction. It is also the most informative.
What the goodwill line is recording
PharmEasy
₹8,364 Cr of acquisition premium, ₹4,850 Cr written down.
Gross goodwill of ₹8,364 Cr reflects the cumulative price paid above fair value of identifiable net assets across acquisitions: Thyrocare Technologies, Aknamed/Akna network (~28 regional pharma distributors), Medlife era entities, Docon, and Nueclear. ₹4,850 Cr (58%) has been recognised as cumulative impairment, primarily routed through the exceptional items line in past P&Ls. ₹175 Cr of incremental impairment was recognised in FY2025 itself. The net carrying value of goodwill at March 2025 is ₹3,513 Cr, larger than the year's revenue growth would close in a decade.
Tata 1mg
₹5.93 Cr of goodwill at the operating-group layer.
The consolidated goodwill of ₹5.93 Cr at the operating-group layer is small relative to PharmEasy's ₹8,364 Cr. The current Tata 1mg consolidated filing does not carry an equivalent goodwill burden at the operating-group layer; the acquisition of the original 1mg entity by Tata Digital in 2021-22 may have been absorbed differently through group-level accounting at Tata Digital, and the operating-group consolidation under Tata 1mg Technologies records what it records. There is no cumulative impairment line equivalent to PharmEasy's at this layer.
→ Broadly the same consumer-health thesis is being expressed through different legal and entity pathways. The PharmEasy consolidated filing visibly carries the acquisition premium and its subsequent impairment cycles. The Tata 1mg consolidated filing does not carry an equivalent goodwill burden at the operating-group layer.
The Funding Contrast
The funding sources sit in different lines on the two consolidated balance sheets.
Borrowings: current
PharmEasy
₹350 Cr
down from ₹2,074 Cr in FY24
Tata 1mg
₹655 Cr
up from ₹365 Cr in FY24
The gap: PharmEasy is paying down concentrated debt facilities. Tata 1mg is expanding working-capital borrowings to fund the group's cash burn plus capex.
Borrowings: non-current
PharmEasy
₹1,684 Cr
down from ₹2,024 Cr
Tata 1mg
₹0 Cr
no non-current borrowings either year
The gap: PharmEasy carries term debt at the parent level. Tata 1mg's borrowings are entirely short-term.
Finance costs (FY2025)
PharmEasy
₹506 Cr
down 30% from ₹728 Cr
Tata 1mg
₹50.12 Cr
up 67% from ₹29.93 Cr
The gap: ₹456 Cr difference in absolute finance cost. PharmEasy's debt service is 10x larger but contracting; Tata 1mg's is much smaller but expanding.
What each funding line records about the source of capital
PharmEasy
Investor equity plus institutional debt.
API Holdings is structured as a Public Limited company that filed and withdrew a DRHP in 2021. The capital stack has historically included multiple equity rounds plus institutional borrowings carried at the parent level. The FY25 halving of borrowings (₹4,098 Cr to ₹2,034 Cr) reflects the post-restructuring deleveraging cycle that followed the IPO withdrawal.
Tata 1mg
Parent equity plus working-capital borrowings.
The funding source is Tata Digital Private Limited, which acquired the original 1mg entity. Pre-acquisition OCRPS held by Tata Digital converted to equity in July 2023. Group-level borrowings of ₹655 Cr are unsecured working-capital lines sitting at the operating subsidiary level. The FY25 ₹290 Cr expansion in borrowings funded the consolidated operating cash burn plus capex.
→ Two consumer-health groups, two different capital stacks, both still funding operations alongside the loss.
Why This Comparison Matters
Both serve the same broad customer category (Indian patients buying medicines and diagnostic tests). Both are loss-making at the consolidated level. By the FY2025 audit, the construction strategy is what most explains the line items.
PharmEasy
Continued multi-entity acquisition expansion. 31 consolidated subsidiaries. ₹4,850 Cr cumulative goodwill impairment. Deleveraging. Net worth positive at ₹3,272 Cr.
Tata 1mg
Post-acquisition expansion largely within a single-parent structure. ₹5.93 Cr of goodwill at the operating-group layer. Expanding working-capital borrowings. Net worth negative at -₹352 Cr.
What Each FY26 Filing Will Record
The FY2026 audits will record specific line items for each entity, independent of forward economics.
What to look for in each FY26 filing
PharmEasy
The goodwill movement schedule.
The FY2025 incremental goodwill impairment was ₹175 Cr, down from ₹1,027 Cr of exceptional items in FY2024. Whether further impairment is recognised in FY2026 records management's view of whether each acquired business's expected economics remain consistent with its carrying value. The exceptional items line is the place where this shows up. Also relevant: whether borrowings continue to compress and finance costs follow.
Tata 1mg
The borrowings and capex line.
The FY2025 audit records ₹290 Cr of borrowings expansion and ₹123 Cr of property additions (up 12x from ₹10 Cr in FY24). Whether the borrowings line stabilises or continues to expand records whether the funding mix at the operating layer continues to depend on debt or shifts back to parent equity. The capex line records whether the FY25 capacity build continues or normalises.
→ Both audits will record FY26 outcomes; neither audit is a forecast. The next year's filing answers each question by recording what happened, not by predicting it.
“Broadly the same consumer-health thesis. Two different legal and entity pathways for capital deployment. The audit shapes are not interchangeable.”
UnpopularVoice editorial read
Read Each Audit
The filing-by-filing breakdown for each company is in its individual analysis. PharmEasy's article covers the 31-subsidiary structure, the gross-vs-net goodwill schedule, and the deleveraging cycle after the IPO withdrawal. Tata 1mg's article covers the standalone-profit-vs-consolidated-loss split, the parent's investment-in-subsidiaries carrying value, and the working-capital borrowings expansion.